Patents for A61P 35 - Antineoplastic agents (221,099)
04/2009
04/15/2009CN101407500A 3,4-diaryl isoxazole-5-amido derivative, and preparation and use thereof
04/15/2009CN101407467A N-substituted arene aniline / polysubstituted diaryl ether compound, preparation and anti-tumor use thereof
04/15/2009CN101407460A Trihydroxy-2-acyl phenylacetate, and preparation and use thereof
04/15/2009CN101407459A Monohydroxy-2-acyl phenylacetate, and preparation and use thereof
04/15/2009CN101406701A Adjuvant capable of improving dendritic cell vaccine efficiency
04/15/2009CN101406700A Mixed immunity antigen and use thereof in establishing monoclonal antibody hybridoma cell strain
04/15/2009CN101406692A Vaccine composition containing transforming growth factor alpha
04/15/2009CN101406663A Medicine for treating cancer and method for producing the same
04/15/2009CN101406657A Chinese medicine compound for treating lung cancer and manufacturing method thereof
04/15/2009CN101406625A Chinese medicinal composition for treating cancer as well as preparation method and use thereof
04/15/2009CN101406624A Chinese medicine composing prescription having functions of regulation, auxiliary treatment for various diseases
04/15/2009CN101406604A Chinese medicine for treating brain tumor
04/15/2009CN101406594A Chinese medicine for treating tumor of lung
04/15/2009CN101406580A Anticancer pain-relieving Chinese medicine and preparation method thereof
04/15/2009CN101406566A Chinese medicine for treating gastric cancer
04/15/2009CN101406564A External-use Chinese medicinal composition formulation and uses thereof
04/15/2009CN101406513A Malaytea scurfpea fruit extract, pharmaceutical composition containing the same, and preparation method and application thereof
04/15/2009CN101406509A Lonicera confusa extract and preparation method and application thereof
04/15/2009CN101406499A Cherimoya inner ester extract as well as extraction method and use thereof in preparing anti-cancer medicine
04/15/2009CN101406486A Method for preparing maggot health-care oral liquid
04/15/2009CN101406475A Use of lapatinib for reversing multi-drug resistance of tumor
04/15/2009CN101406473A Use of dihydropyrimidine compound and pharmaceutical composition containing the same
04/15/2009CN101406470A Use of heterocyclic ring derivative of pyridine and pharmaceutical composition containing the same
04/15/2009CN101406455A Strychnine composite phospholipid liposome, and preparation method thereof and use in pharmacy
04/15/2009CN101406453A Pharmaceutical compositions for oral and topical administration
04/15/2009CN101406451A Rebescensine A intravenous emulsion and preparation method thereof
04/15/2009CN101406217A Amandine milk powder
04/15/2009CN100478689C Polypeptide and use thereof
04/15/2009CN100478344C Use of compound metabolized by diaporthe phaseolorum fungus
04/15/2009CN100478019C Medicinal pill, watered pill, honeyed pill for treating liver cancer and method for preparing same
04/15/2009CN100478018C A medicine for treating liver cancer and method for preparing same
04/15/2009CN100478016C Sarcandra solid dispersion and its preparing method
04/15/2009CN100478014C Chinese medicinal preparation for treating lung cancer and production thereof
04/15/2009CN100478009C Chinese medicine for anti-tumor and its preparing method
04/15/2009CN100478003C Rabdosia extraction method
04/15/2009CN100477998C Instant pyrobixi freeze-drying powdery injection and its production
04/15/2009CN100477993C Compositions and uses of et743 for treating cancer
04/15/2009CN100477991C Oral formulation of neogambogic acid for treating tumor
04/15/2009CN100477988C Use of pogostemonis alkane type sesquiterpene compound as vegetative female sex normone
04/14/2009US7517996 methyl 3-(4-{4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-isoxazolyl}-benzylsulfanyl)propionate; compounds inhibit the physiological activity of lysophosphatidic acid (LPA); treatment of fibrosis of organs (liver, kidney, lung, and the like), hepatic disease
04/14/2009US7517994 Heterocyclic inhibitors of MEK and methods of use thereof
04/14/2009US7517989 Piperidine derivatives useful as modulators of chemokine receptor activity
04/14/2009US7517987 Interleukin converting enzyme inhibitors such as 5-Fluoro-4-oxo-3-(2-(6-oxo-6H-pyrimidin-1-yl)-butyrylamino)-pentanoic acid, administered as modulators of cell apoptosis and inflammation
04/14/2009US7517974 Blood coagulation factor; nucleotide sequence encodes polypeptide; amino acid sequence differs in 1-15 amino acid residues and comprises an introduced in vivo N-glycosylation site; substitution V253N; coagulation related disorders
04/14/2009US7517971 Muteins of human telomerase reverse transcriptase lacking telomerase catalytic activity
04/14/2009US7517962 TWEAK receptor
04/14/2009US7517907 specific activator of retinoic acid receptors subtype beta; 6-[3-adamantan-1-yl-4-(2,2-dimethyl[1,3]dioxoian-4-ylmethoxy)phenyl]naphthalene-2-carboxylic acid; useful in human or veterinary medicine; for body/hair hygiene, treating acne-prone skin, promoting hair regrowth, limiting hair loss, dry skin
04/14/2009US7517902 1-[4-(3-amino-7-fluoro-1H-indazol-6-yl)phenyl]-3-(2-fluoro-5-trifluoromethyl-phenyl)urea; protein kinases (Vascular Endothelial Growth Factor Receptor 2 and Tie-2), inhibitor; anticarcinogenic, antiinflammatory agent; neovascularization, lung and breast cancer, rheumatoid arthritis
04/14/2009US7517895 Synthetic diazonamides
04/14/2009US7517887 Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
04/14/2009US7517883 Solubilized topoisomerase poisons
04/14/2009US7517879 Pyrrolidine derivatives as factor Xa inhibitors
04/14/2009US7517861 Containing unmethylated CpG dinucleotides; redirection of a Th2 response to a Th1 response; atopic diseases, dermatitis
04/14/2009US7517858 Prodrugs of pharmaceuticals with improved bioavailability
04/14/2009US7517853 Biodrugs for treatment of neoplasia and acromegaly
04/14/2009US7517670 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
04/14/2009US7517661 Methods of screening for ligands for FPRL2
04/14/2009US7517646 Provides functional molecule having an affinity and specificity to a target comparable to the affinity and specificity of an antibody against an antigen; modified oligonucleotide sequence
04/14/2009US7517526 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
04/14/2009US7517524 Monoclonal antibody or an antigen-binding fragment thereof which binds to human VEGF-B (vascular endothelial growth factor) produced by hybridoma; neovascularization diseases; antitumor, anticarcinogenic, antiinflammatory, and antimetastasis agents; rheumatoid arthritis; angiogenesis inhibitors
04/14/2009CA2530474C Remedy for sarcoidosis and method of treating the same
04/14/2009CA2417050C Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
04/14/2009CA2396865C Farnesyl protein transferase inhibitors for treating breast cancer
04/14/2009CA2386190C Regulators of the hedgehog pathway, compositions and uses related thereto
04/14/2009CA2385863C New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds
04/14/2009CA2371789C Novel guanidine derivatives as inhibitors of cell adhesion
04/14/2009CA2337797C Naaladase inhibitors useful as pharmaceutical compounds and compositions
04/14/2009CA2219460C Lhrh antagonist peptides
04/14/2009CA2208237C Nuclear protein serine/threonine kinases
04/09/2009WO2009046416A1 Anilinopyrimidines as jak kinase inhibitors
04/09/2009WO2009046294A2 Treatment of proliferative disorders using antibodies to psma
04/09/2009WO2009046220A2 Lipopeptides for delivery of nucleic acids
04/09/2009WO2009046123A2 Nlrr-1 antagonists and uses thereof
04/09/2009WO2009045497A1 Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
04/09/2009WO2009045476A1 Pyrimidinedione derivatives
04/09/2009WO2009045345A1 Metabolic degradation inhibitors for anti-hyperproliferative agents
04/09/2009WO2009045179A1 Taz/wwtr1 for diagnosis and treatment of cancer
04/09/2009WO2009045175A1 Pyrimidine substituted purine derivatives
04/09/2009WO2009045174A1 2-morpholinylpurines as inhibitors of pi3k
04/09/2009WO2009044899A1 Nucleic acid capable of regulating the proliferation of cell
04/09/2009WO2009044895A1 Composition inhibiting the expression of target gene
04/09/2009WO2009044788A1 Benzoxazinone derivative
04/09/2009WO2009044555A1 Preparation and method of administering vaccine and iontophoresis device using the preparation
04/09/2009WO2009044554A1 Preparation and method of administering vaccine and iontophoresis device using the preparation
04/09/2009WO2009044439A1 Composition for preventing or treating liver disease
04/09/2009WO2009044311A1 Thiophene-2-carboxamide derivatives as modulators of ccr9 receptor
04/09/2009WO2009044273A2 Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
04/09/2009WO2009044173A2 Methods of treating cancer using notch pathway inhibitors
04/09/2009WO2009044162A1 Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use
04/09/2009WO2009044153A2 Inhibitors and uses
04/09/2009WO2009044019A2 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof
04/09/2009WO2009044018A2 Derivatives of 1-oxo-1,2-dihydroisoquinoline-5-carboxamides and of 4-oxo-3,4-dihydroquinazoline-8-carboxamides, preparation thereof and application thereof in therapeutics
04/09/2009WO2009043960A1 Anti-tumour agents based on viral protein a238l
04/09/2009WO2009043900A1 Drug transfer based on coenzyme a and acyl carrier protein
04/09/2009WO2009043899A1 Drug transfer into living cells
04/09/2009WO2009043836A1 A composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases.
04/09/2009WO2009043538A1 Artemisinin derivatives for the treatment of melanoma
04/09/2009WO2009043529A1 Thyrotropin releasing hormone for therapeutic applications
04/09/2009WO2009043528A1 Substance p and thyrotropin releasing hormone for therapeutic applications
04/09/2009WO2009043527A2 Therapeutic use of human growth hormone 1-43